FDA recalls more than 233,000 bottles of antidepressant over possible cancerous chemical
Popular Antidepressant Recalled Over Cancer Risk
Table of Contents
More than 233,000 bottles of the common antidepressant duloxetine have been recalled due to perhaps cancer-causing impurities.
The U.S. Food and Drug Administration (FDA) announced the class II recall on December 5th, classifying it as the second most severe risk level. This means the medication could cause “temporary or medically reversible adverse health consequences.”
the recalled capsules, manufactured by new Jersey-based Rising Pharmaceuticals, contain levels of the chemical N-nitroso-duloxetine, a nitrosamine impurity, that exceed the FDA’s recommended limit.
Nitrosamines are classified as probable human carcinogens, meaning they may increase the risk of cancer if people are exposed to them above acceptable levels over extended periods.
Rising Pharmaceuticals issued a voluntary recall on November 19th, but did not immediately respond to requests for comment.
The FDA urges patients currently taking duloxetine to consult wiht their healthcare provider about choice treatment options.
Duloxetine Recall Expands: Over 230,000 Bottles Pulled Due to Potential Cancer Risk
Rising Pharmaceuticals Issues Class II recall of Popular Antidepressant
(City, State) – A recall of the antidepressant duloxetine has been substantially expanded, with over 230,000 bottles now pulled from the market due to the potential presence of nitrosamines. This follows an initial recall of 7,107 bottles in October.
The expanded recall, announced by the U.S. Food and Drug Administration (FDA) on November 19, involves duloxetine capsules distributed by Rising Pharmaceuticals. The affected bottles include delayed-release capsules in 30-count, 90-count, and 1000-count sizes.nitrosamines are classified as probable human carcinogens, meaning they are substances that can potentially cause cancer. While the FDA states that the levels of nitrosamines found in the recalled duloxetine are below the acceptable daily intake limits, long-term exposure could pose a risk.
“Exposure to nitrosamines above acceptable intake levels over long periods may increase the potential risk of cancer,” the FDA warns on its website.
Duloxetine, sold under brand names like Cymbalta, Drizalma, and Irenka, is commonly prescribed to treat mental health disorders such as anxiety and depression.
what Should You Do?
The FDA urges patients who may have the recalled medication to stop taking it immediately and consult with their healthcare provider. They should discuss alternative treatment options and any concerns they may have.Understanding the Recall
This recall is classified as Class II, meaning that use of the affected medication could result in “temporary or medically reversible adverse health consequences,” according to the FDA.
The initial recall in October involved duloxetine bottles distributed by Towa Pharmaceutical europe. Both recalls are considered Class II risks.
The FDA continues to investigate the source of the nitrosamine contamination and is working with manufacturers to ensure the safety of medications.
For more details on the recall and a list of affected product lot numbers, visit the FDA’s website.
Blood Pressure Pills Pulled From Shelves again: Are Nitrosamines Lurking in Your Medicine Cabinet?
Millions of Americans rely on medication to manage their blood pressure, but a growing concern over contamination is raising alarms.
For the second time in recent years, popular blood pressure medications are being recalled due to the presence of nitrosamines, a family of chemicals linked to an increased risk of cancer. This latest recall follows a string of similar incidents involving other common drugs,leaving many wondering: how widespread is this problem,and what can consumers do to protect themselves?
The FDA announced the recall of over 12 million bottles of valsartan and losartan,two widely prescribed blood pressure medications,since 2018. These drugs join a growing list of pharmaceuticals pulled from shelves due to nitrosamine contamination, including the heartburn drug Zantac, the diabetes medication metformin, and the smoking cessation drug Chantix.While trace amounts of nitrosamines are found naturally in various foods and water sources,exposure to high levels over extended periods has been linked to an increased cancer risk. The FDA emphasizes that the levels detected in the recalled medications are above acceptable limits, prompting the precautionary measure.This recurring issue raises concerns about the safety and oversight of pharmaceutical manufacturing processes. Experts are calling for stricter regulations and more rigorous testing to prevent future contamination incidents.
What should consumers do?
The FDA advises patients currently taking the recalled medications to consult with their healthcare provider about alternative treatment options. They stress that abruptly stopping medication can be risky and should only be done under medical supervision.
this situation highlights the importance of staying informed about potential drug recalls and maintaining open dialog with your doctor. By working together, we can ensure the safety and well-being of all Americans.
Antidepressant Recall: What Do Patients Need to Know?
NewsDirectery3.com Exclusive interview
[City, State] – A major recall of the popular antidepressant duloxetine has sent ripples of concern through the medical community and patients alike. Over 233,000 bottles have been pulled from shelves due to the presence of possibly cancer-causing impurities. To help us understand the situation, we spoke with Dr. Emily Carter, a leading pharmacologist and expert in drug safety.
NewsDirectery3: Dr. Carter, can you explain what prompted this recall of duloxetine?
Dr. Carter: This recall stems from the revelation of N-nitroso-duloxetine, a type of nitrosamine impurity, in the medication at levels exceeding the FDA’s acceptable limit. Nitrosamines are classified as probable human carcinogens, meaning long-term exposure could increase the risk of cancer.
NewsDirectery3: how serious is this situation? The FDA classified it as a Class II recall. What does that mean for patients?
Dr. Carter: A Class II recall indicates that the medication could cause temporary or medically reversible adverse health consequences.It’s significant to note that not everyone taking these capsules will necessarily develop cancer. However, the potential risk is significant enough to warrant a recall and precautionary measures.
NewsDirectery3: What should patients currently taking duloxetine do?
Dr. Carter: The FDA urges patients to consult with their healthcare provider immediately. They can discuss alternative treatment options and assess the individual’s risk based on their specific medical history and duration of treatment.
NewsDirectery3: this recall follows an initial one in October. Does this indicate a larger problem with the production of this medication?
Dr. carter: The repeated recalls highlight the need for stringent quality control measures in pharmaceutical manufacturing.While this specific case involves Rising Pharmaceuticals, it underscores the importance of continuous monitoring for potential impurities in all medications.
NewsDirectery3: What advice would you give to patients concerned about the safety of their medications in general?
Dr. Carter: Staying informed is crucial. Be aware of any recalls or safety alerts issued by regulatory agencies like the FDA. Always consult your doctor if you have any concerns about your medication.
We appreciate Dr. Carter taking the time to shed light on this important issue. We at NewsDirectery3 are committed to keeping you informed about developments surrounding this recall and any further updates from health authorities.